


CLAIMS

1. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of cancer in a patient in need thereof;

wherein the pharmaceutical composition comprises, as an active ingredient, a compound of formula (I):



wherein:

R₁ represents

a hydrogen or halogen atom,
 an alkyl group optionally substituted with -COOR₅,
 an alkenyl group optionally substituted with -COOR₅,
 a -COOR₅ or -CONR₅R₆ group,
 an -NR₅COR₆ or -NR₅-SO₂R₆ group,
 an -OR₅, -O-Alk-OR₅, -O-Alk-COOR₅, -O-Alk-OR₅, -O-Alk-NR₅R₆ or
 -O-Alk-NR₇R₈ group

or

an aryl group, or a heteroaryl group, said aryl or heteroaryl group being optionally substituted with one or more groups selected from: halogen atoms, alkyl groups, cycloalkyl groups, -COOR₅, -CF₃, -OCF₃, -CN, -C(NH₂)NOH, -ORR₅, -OR₅, -O-Alk-COOR₅, -O-Alk-NR₅R₆, -O-Alk-NR₇R₈, -Alk-OR₅, -Alk-COOR₅, -CONR₅R₆, -CO-NR₅-OR₆, -CO-NR₅-SO₂R₇, -CONR₅-Alk-NR₅R₆, -CONR₅-Alk-NR₇R₈, -Alk-NR₅R₆, -NR₅R₆, -NC(O)N(CH₃)₂, -CO-Alk, -CO(OAlk)_nOH, -COO-Alk-NR₅R₆, -COO-Alk-NR₇R₈ and 5-membered heteroaryl groups, said heteroaryl groups being optionally substituted with one or more groups selected from halogen atoms and alkyl, -CF₃, -CN, -COOR₅, -Alk-OR₅, -Alk-COOR₅, -CONR₅R₆, -CONR₇R₈, -CO-NR₅-OR₆, -CO-NR₅-SO₂R₆, -NR₅R₆ and -Alk-NR₅R₆ groups, or with a hydroxyl group or with an oxygen atom,

n is an integer ranging from 1 to 3,


R₂ represents:

a hydrogen atom,


an alkyl group,

a phenyl group optionally substituted with one or more alkyl groups,


- R_3 and R_4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below:



(A)



(B)



(C)

in which the wavy lines represent the phenyl nucleus to which R_3 and R_4 are attached and:

R_a represents a hydrogen atom or an alkyl, haloalkyl, $-\text{Alk}-\text{CF}_3$, $-\text{Alk}-\text{COOR}_5$, $-\text{Alk}'-\text{COOR}_5$, $-\text{Alk}-\text{CONR}_5\text{R}_6$, $-\text{Alk}'-\text{CONR}_5\text{R}_6$, $-\text{Alk}-\text{CONR}_7\text{R}_8$, $-\text{Alk}-\text{NR}_5\text{R}_6$, $-\text{AlkCONR}_5\text{OR}_6$, $-\text{Alk}-\text{NR}_7\text{R}_8$, $-\text{Alk}-\text{cycloalkyl}$, $-\text{Alk}-\text{O}-\text{R}_5$, $-\text{Alk}-\text{S}-\text{R}_5$, $-\text{Alk}-\text{CN}$, $-\text{OR}_5$, $-\text{OAlkCOOR}_5$, $-\text{NR}_5\text{R}_6$, $-\text{NR}_5-\text{COOR}_6$, $-\text{Alk}-\text{aryl}$, $-\text{Alk}-\text{O}-\text{aryl}$, $-\text{Alk}-\text{O}-\text{heteroaryl}$, $-\text{Alk}-\text{heteroaryl}$ or heteroaryl group, where the aryl or heteroaryl group is optionally substituted with one or more halogen atoms and/or alkyl, cycloalkyl, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{O}-\text{R}_5$ or $-\text{S}-\text{R}_5$ groups,

R_a' represents a hydrogen atom or a linear, branched, cyclic or partially cyclic alkyl group, or an $-\text{Alk}-\text{OR}_5$, $-\text{Alk}-\text{NR}_5\text{R}_6$ or $-\text{Alk}-\text{NR}_7\text{R}_8$ group, R_a' being optionally substituted with one or more halogen atoms,

R_b represents a hydrogen atom or an alkyl or $-\text{Alk}-\text{COOR}_5$ group,

R_b' represents a hydrogen atom or an alkyl, haloalkyl, cycloalkyl, phenyl or $-\text{Alk}-\text{COOR}_5$ group,

R_c represents a hydrogen atom or an alkyl, $-\text{CN}$, $-\text{COOR}_5$, $-\text{CO}-\text{NR}_5\text{R}_6$, $-\text{CONR}_7\text{R}_8$, $-\text{CO}-\text{NR}_5-\text{Alk}-\text{NR}_5\text{R}_6$, $-\text{CONR}_5-\text{Alk}-\text{OR}_5$, $-\text{CONR}_5\text{SO}_2\text{R}_5$, $-\text{Alk}-\text{aryl}$, a heteroaryl or $-\text{Alk}-\text{heteroaryl}$ group, where the aryl or heteroaryl group is optionally substituted with one or more halogen atoms and/or alkyl, cycloalkyl, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{O}-\text{alkyl}$ or $-\text{S}-\text{alkyl}$ groups,

R_c' represents a hydrogen atom or an alkyl group,

R_c'' represents a hydrogen atom or an alkyl, alkenyl, haloalkyl, cycloalkyl, $-\text{Alk}-\text{NR}_5\text{R}_6$, $-\text{Alk}-\text{NR}_7\text{R}_8$, $-\text{Alk}-\text{OR}_5$ or $-\text{Alk}-\text{SR}_5$ group,

R₅ and R₆, which may be identical or different, represent hydrogen atoms, haloalkyl groups or alkyl groups, cycloalkyl groups or an Ms group,

R₇ and R₈, which may be identical or different, represent hydrogen atoms or alkyl or phenyl groups, or else R₇ and R₈ together form a 3- to 8-membered saturated ring which can optionally contain a heteroatom,

Alk represents a linear or branched alkylene chain, and

Alk' represents a linear, branched, cyclic or partially cyclic alkylene chain,


optionally in the form of a pharmaceutically acceptable salt thereof;

optionally in combination with one or more suitable inert excipients.

2. The use according to claim 1, wherein the pharmaceutical composition is to be administered in combination with one or more anticancer active ingredient(s) and/or with radiotherapy and/or with any anti-vascular endothelial growth factor (VEGF) treatment.

3 Use of ~~the~~ a pharmaceutical composition ~~as defined in claim 1,~~ in the manufacture of a medicament for the treatment of cardiovascular diseases, diseases related to complications that occur following the implantation of endovascular stents and/or aortocoronary bypasses or other vascular grafts, cardiac hypertrophy, vascular complications of diabetes, liver, kidney and lung fibroses, neuropathic pain, chronic inflammatory diseases, prostatic hyperplasia, psoriasis, clear cell acanthoma, osteoarthritis, achondroplasias (ACH), hypochondroplasias (HCH), TD (thanatophoric dysplasia), obesity, and macular degeneration, in a patient in need thereof;

wherein the pharmaceutical composition comprises, as an active ingredient, a compound of formula (I):



wherein:

R₁ represents

a hydrogen or halogen atom,

an alkyl group optionally substituted with -COOR₅,

an alkenyl group optionally substituted with -COOR₅,

a -COOR₅ or -CONR₅R₆ group,

an -NR₅COR₆ or -NR₅-SO₂R₆ group,

an $-OR_5$, $-O-Alk-OR_5$, $-O-Alk-COOR_5$, $-O-Alk-NR_5R_6$ or $-O-Alk-NR_7R_8$ group

or

an aryl group, or a heteroaryl group, said aryl or heteroaryl group being optionally substituted with one or more groups selected from: halogen atoms, alkyl groups, cycloalkyl groups, $-COOR_5$, $-CF_3$, $-OCF_3$, $-CN$, $-C(NH_2)NOH$, $-OR_5$, $-O-Alk-COOR_5$, $-O-Alk-NR_5R_6$, $-O-Alk-NR_7R_8$, $-Alk-OR_5$, $-Alk-COOR_5$, $-CONR_5R_6$, $-CO-NR_5-OR_6$, $-CO-NR_5-SO_2R_7$, $-CONR_5-Alk-NR_5R_6$, $-CONR_5-Alk-NR_7R_8$, $-Alk-NR_5R_6$, $-NR_5R_6$, $-NC(O)N(CH_3)_2$, $-CO-Alk$, $-CO(OAlk)_nOH$, $-COO-Alk-NR_5R_6$, $-COO-Alk-NR_7R_8$ and 5-membered heteroaryl groups, said heteroaryl groups being optionally substituted with one or more groups selected from halogen atoms and alkyl, $-CF_3$, $-CN$, $-COOR_5$, $-Alk-OR_5$, $-Alk-COOR_5$, $-CONR_5R_6$, $-CONR_7R_8$, $-CO-NR_5-OR_6$, $-CO-NR_5-SO_2R_6$, $-NR_5R_6$ and $-Alk-NR_5R_6$ groups, or with a hydroxyl group,

n is an integer ranging from 1 to 3,


R_2 represents:

a hydrogen atom,


an alkyl group,

a phenyl group optionally substituted with one or more alkyl groups,


- R_3 and R_4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below:



(A)



(B)



(C)

in which the wavy lines represent the phenyl nucleus to which R_3 and R_4 are attached and:

R_a represents a hydrogen atom or an alkyl, haloalkyl, $-Alk-CF_3$, $-Alk-COOR_5$, $-Alk'-COOR_5$, $-Alk-CONR_5R_6$, $-Alk'-CONR_5R_6$, $-Alk-CONR_7R_8$, $-Alk-NR_5R_6$, $-AlkCONR_5-OR_6$, $-Alk-NR_7R_8$, $-Alk-cycloalkyl$, $-Alk-O-R_5$, $-Alk-S-R_5$, $-Alk-CN$, $-OR_5$, $-OAlkCOOR_5$, $-NR_5R_6$, $-NR_5-COOR_6$, $-Alk-aryl$, $-Alk-O-aryl$, $-Alk-O-heteroaryl$, $-Alk-heteroaryl$ or heteroaryl group, where the aryl or heteroaryl group is optionally substituted with one or more halogen atoms and/or alkyl, cycloalkyl, $-CF_3$, $-OCF_3$, $-O-R_5$ or $-S-R_5$ groups,

R_a represents a hydrogen atom or a linear, branched, cyclic or partially cyclic alkyl group, or an -Alk-OR₅, -Alk-NR₅R₆ or -Alk-NR₇R₈ group, R_a being optionally substituted with one or more halogen atoms,

R_b represents a hydrogen atom or an alkyl or -Alk-COOR₅ group,

R_b' represents a hydrogen atom or an alkyl, haloalkyl, cycloalkyl, phenyl or -Alk-COOR₅ group,

R_c represents a hydrogen atom or an alkyl, -CN, -COOR₅, -CO-NR₅R₆, -CONR₇R₈, -CO-NR₅-Alk-NR₅R₆, -CONR₅-Alk-OR₅, -CONR₅SO₂R₅, -Alk-aryl, a heteroaryl or -Alk-heteroaryl group, where the aryl or heteroaryl group is optionally substituted with one or more halogen atoms and/or alkyl, cycloalkyl, -CF₃, -OCF₃, -O-alkyl or -S-alkyl groups,

R_c represents a hydrogen atom or an alkyl group,

R_c' represents a hydrogen atom or an alkyl, alkenyl, haloalkyl, cycloalkyl, -Alk-NR₅R₆, -Alk-NR₇R₈, -Alk-OR₅ or -Alk-SR₅ group,

R₅ and R₆, which may be identical or different, represent hydrogen atoms, haloalkyl groups or alkyl groups, cycloalkyl groups or an Ms group,

R₇ and R₈, which may be identical or different, represent hydrogen atoms or alkyl or phenyl groups, or else R₇ and R₈ together form a 3- to 8-membered saturated ring which can optionally contain a heteroatom,

Alk represents a linear or branched alkylene chain, and

Alk' represents a linear, branched, cyclic or partially cyclic alkylene chain,

optionally in the form of a pharmaceutically acceptable salt thereof;

optionally in combination with one or more suitable inert excipients.

4. The use according to claim 1, wherein said cancer is selected from carcinomas which have a high degree of vascularization, cancers selected from metastases, melanomas, gliomas, lymphomas, leukaemias, and thrombopenias.
5. The use according to claim 3, wherein the cardiovascular diseases is selected from atherosclerosis and post-angioplasty restenosis.
6. The use according to claim 3, wherein the vascular complications of diabetes is selected from diabetic retinopathies.
7. The use according to claim 3, wherein the chronic inflammatory diseases is selected from rheumatoid arthritis and inflammatory bowel disease (IBD).
8. The use according to claim 3, wherein the macular degeneration is age related macular degeneration (ARMD).